FDA approves USGI Medical’s pivotal study of the POSE2.0 procedure for primary obesityThe FDA has approved an USGI Medical’s Investigational Device Exemption application to conduct a pivotal study of its POSE2.0...
USGI Medical completes Pilot Study of the POSE2.0 incisionless weight loss procedureThe FDA has acknowledged the successful completion of a pilot study of USGI Medical’s incisionless, endoscopic gastroplasty procedure,...
FDA approves expansion of POSE2.0 US pilot study evaluating incisionless weight loss procedureThe FDA has approved the expansion of a US- pilot study of the USGI Medical’s non-invasive, endoscopic procedure, known as POSE2.0. The...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure2 days ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity2 days ago